The most recent trading session ended with Gilead Sciences (GILD) standing at $105.87, reflecting a -1.53% shift from the previouse trading day's closing. This change lagged the S&P 500's daily loss ...

On Wednesday, Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025).

The landscape for so-called PrEP drugs is evolving rapidly: While Gilead expects FDA approval in June of lenacapvir to be injected twice-a-year to halt the AIDS virus, it is making plans for the ...

Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New launches like Livdelzi provide growth opportunities but are unlikely to ...

conducted in the immune system disorders lupus and Sjögren's syndrome, failed to meet their primary endpoints, according to comments made on Gilead’s third-quarter results call. Lupus is a ...

Warhammer 40,000: Wrath & Glory lets players build their groups from different archetypes. They are brought together as ...

In recent trading, shares of Gilead Sciences Inc (Symbol: GILD) have crossed above the average analyst 12-month target price of $111.77, changing hands for $112.26/share. When a stock reaches the ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months.

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

Gilead Sciences (GILD ... As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into ...